Thus, durable high levels of GC during cancer progression could abolish the efficacy of immune-dependent cancer therapies through changing the cancer cell and immune cell-containing microenvironment, the proportion of circulating immune cells, circulating IL-6 levels, and the balance between circulating CD8+PD-1+ and CD4+PD-1+ T cells. The gene discussed is CD4; the disease is cancer.